Short-Term Debt to Equity: Oncternal Therapeutics Inc (ONCT)

Oncternal Therapeutics (ONCT) is currently reducing its workforce to a core team of researchers to protect its intellectual property. The company's revenues will be based on bringing breast cancer and severe leukemia drugs to market. This price chart illustrating value trends shows the metric at 0.02, confirming the status of a developer gaining medical authority through the fight against rare malignant pathologies.

For an investor assessing the creditworthiness of an issuer, this ratio, which compares long-term liabilities to net equity, serves as an indicator of the risk of shareholder value dilution; in the context of Oncternal Therapeutics (ONCT), which maintains a boutique scientific research format, the current level of short-term liabilities to equity on the GURU.Markets platform demonstrates the company's ability to fund clinical trials without imposing a critical debt burden on its own equity.